Press-release for stocks for snynf

symbols : Snynf crawled time : 12:00

save search

Sanofi Cuts Jobs in U.S. Vaccines Division as Part of Restructuring
Published: 2024-04-19 (Crawled : 12:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| 0.0% | O: 0.82% H: 0.0% C: 0.0%
sanofi

Quebec's INESSS recommends BEYFORTUS for the prevention of RSV for all infants 8 months of age and younger(1)
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| 0.0% | O: 0.0% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -1.81% | O: -1.81% H: 0.0% C: 0.0%
beyfortus for rsv

AstraZeneca Expands Fasenra’s Label to Children Aged 6 to 11 with Severe Asthma
Published: 2024-04-12 (Crawled : 12:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -4.0% | O: -3.02% H: 0.0% C: 0.0%
label children astrazeneca

MPM BioImpact Appoints Frank Neumann, M.D., Ph.D., Distinguished Expert in Clinical Development, as Entrepreneur Partner
Published: 2024-04-11 (Crawled : 12:00) - mpmcapital.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -1.64% | O: -100.0% H: NaN% C: Infinity%
VSTM | $9.86 -3.62% -3.75% 150K

Health Technology

| -9.59% | O: -0.4% H: 4.84% C: 4.79%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -3.95% | O: 0.05% H: 0.0% C: 0.0%

BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMAGE
Published: 2024-04-03 (Crawled : 12:00) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -4.59% | O: 0.69% H: 0.0% C: 0.0%
patent dpx international

DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating Results
Published: 2024-03-28 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -7.02% | O: -1.17% H: 0.0% C: -0.89%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -8.47% | O: -0.96% H: 0.0% C: 0.0%
DRIO | $1.17 1.74% 1.71% 50K

Health Technology

| -23.03% | O: -4.61% H: 14.48% C: 5.52%
financial results

Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
Published: 2024-03-27 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -7.26% | O: -0.26% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -7.5% | O: 1.06% H: 0.0% C: 0.0%
MRNA S | $101.44 -0.55% -0.55% 2.6M

Health Technology

| -3.7% | O: 2.02% H: 1.41% C: 0.92%
vaccine trials

Dyne Therapeutics Announces CEO Transition
Published: 2024-03-25 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -1.09% | O: -100.0% H: NaN% C: Infinity%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -5.33% | O: 0.42% H: 0.0% C: 0.0%
DYN | $23.89 1.02% 1.0% 970K

Health Technology

| -12.78% | O: -13.24% H: 11.02% C: 6.37%
BIIB | $194.39 2.03% 1.99% 1.6M

Health Technology

| -10.52% | O: -0.15% H: 0.23% C: -0.5%
ceo therapeutics

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
Published: 2024-03-21 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -2.29% | O: 0.14% H: 0.24% C: 0.24%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -3.83% | O: 0.3% H: 0.0% C: 0.0%
CTMX | $1.67 -3.47% -3.59% 510K

Health Technology

| -18.06% | O: -1.76% H: 3.59% C: 0.45%
therapeutics

Morphic Appoints Dr. Simon Cooper as Chief Medical Officer
Published: 2024-03-19 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -2.31% | O: -0.02% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -5.25% | O: -1.51% H: 0.0% C: 0.0%
MORF | $28.0 1.78% 1.75% 380K

Health Technology

| -16.71% | O: -1.58% H: 5.18% C: 2.95%
cooper medical simon

GRO Biosciences Expands Executive Team with Appointment of Biopharma Veteran Tracey Lodie, PhD as Chief Development Officer
Published: 2024-03-18 (Crawled : 12:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -6.01% | O: -0.81% H: 0.0% C: 0.0%
biopharma

EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet
Published: 2024-03-08 (Crawled : 12:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -5.38% | O: -0.08% H: 0.0% C: 0.0%
REGN | $896.27 0.26% 0.25% 500K

Health Technology

| -7.41% | O: 0.0% H: 0.27% C: -0.46%
eylea lancet macular injection diabetic

Clinical trials market size in US to grow by USD 5.9 billion from 2022 to 2027, The rise in the number of clinical trials of drugs is the key factor driving market growth, Technavio
Published: 2024-03-06 (Crawled : 12:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -1.01% | O: 0.0% H: 0.8% C: 0.8%
TMO | News | $544.78 0.6% 0.0% 1.7M

Health Technology

| -8.83% | O: 0.64% H: 1.7% C: 0.54%
NVS | $94.36 1.93% 0.0% 2.3M

Health Technology

| -8.83% | O: 0.2% H: 0.71% C: 0.33%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -4.29% | O: -0.45% H: 0.0% C: 0.0%
ICLR | $288.32 -1.2% -1.21% 640K

Health Technology

| -12.96% | O: 2.54% H: 0.22% C: -2.44%
trials key market

Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma
Published: 2024-03-06 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -1.01% | O: 0.0% H: 0.8% C: 0.8%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -4.29% | O: -0.45% H: 0.0% C: 0.0%
IPHA | $2.48 5.53% 5.24% 9.4K

Health Technology

| -8.56% | O: 0.78% H: 1.93% C: 0.97%
iph6501 first study

Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
Published: 2024-02-22 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -3.13% | O: 0.26% H: 1.36% C: 1.36%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -3.44% | O: 1.67% H: 0.0% C: 0.0%
KYMR | $33.965 -3.29% -3.4% 630K

Health Technology

| -9.18% | O: 2.92% H: 7.24% C: 1.73%
business year update therapeutics financial results

Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
Published: 2024-02-21 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -1.49% | O: 1.7% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -3.99% | O: -0.57% H: 0.0% C: 0.0%
REGN | $896.27 0.26% 0.25% 500K

Health Technology

| -4.82% | O: 0.54% H: 0.63% C: 0.09%
fda review treatment

ECO Animal Health Appoints Dr. Joachim Hasenmaier as Non-Executive Director
Published: 2024-02-12 (Crawled : 12:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology